The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

csftherapeutics.com

Founded Year

2006

Stage

Unattributed VC | Alive

Total Raised

$4M

Last Raised

$4M | 15 yrs ago

About CSF Therapeutics

CSF Therapeutics is developing a cerebral blood flow device to prevent neurological debilitation and death, affecting more than 10 million individuals in the US alone, and includes indications such as stroke and Alzheimer's disease. Based on the research at The Cleveland Clinic, CSF Therapeutics' device is designed to increase cerebral blood flow indefinitely without affecting vascular or systemic function.

CSF Therapeutics Headquarter Location

10265 Carnegie Avenue

Cleveland, Ohio, 44106,

United States

216-444-5757

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CSF Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CSF Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CSF Therapeutics Patents

CSF Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/29/2010

4/21/2015

Neurotrauma, Ventricular System, Neurology, Cardiovascular physiology, Fluid dynamics

Grant

Application Date

4/29/2010

Grant Date

4/21/2015

Title

Related Topics

Neurotrauma, Ventricular System, Neurology, Cardiovascular physiology, Fluid dynamics

Status

Grant

You May Also Like

E
EndGenitor Technologies

EndGenitor scientists are also engaged in exciting research to novel methods for stimulating and promoting blood vessel formation and growth.

I
ImaRx Therapeutics

We are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen.In addition to the brain and the lungs, blood clots can block blood flow and cause damage to other tissues in the body such as the heart, in case of coronary arterial disease, and the legs and other extremities, in case of peripheral vascular disease. We believe our development and research stage products may address significant unmet medical needs not only for stroke but also for clot-induced damage in tissues other than the brain.

A
Angiogenix

Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be injected directly into peripheral tissue and used with proven catheter technologies for cardiovascular applications. Angiogenix is located in Burlingame, California.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.